老年人前列腺良性增生与脂质代谢异常的关系研究及阿伐他汀钙疗效分析

Correlation between benign prostate hyperplasia and abnormal lipid metabolismand efficacy of atorvastatin cal-cium in the elderly patients.

目的了解老年人前列腺良性增生（BPH）与脂质代谢异常的相关性，并初步探讨降脂药物阿伐他汀钙对改善BPH的作用。方法纳入我院2010年1月-2011年1月门诊男性患者104例为观察对象；同时纳入非脂质代谢异常的同年龄段男性110例为对照组。检测血总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL—C）、高密度脂蛋白胆固醇（HDL—C）等水平以及超声测量并计算前列腺体积（PV）。对于脂质代谢异常患者，给予20mg／d阿伐他汀钙治疗，并观察上述指标变化。结果脂质代谢异常患者平均PV（54．23±27．33mm^3）明显大于对照组（41．87±23．64mm^3，P〈0．05）。同时，脂质代谢异常患者并发前列腺良性增生的比例（88．5％）明显大于对照组（71．8％，P〈0．05）。与治疗前对比，脂质代谢异常患者服用20mg／d阿伐他汀钙6m，PV值无显著性改变，但服药1年PV值明显减小[（51．87±15．23mm^3）～（47．34±11．66mm3）]，（P〈0．05）。结论老年人前列腺良性增生与脂质代谢异常有关，长期服用阿伐他汀钙有利于改善前列腺良性增生。

Objective To investigate the correlation between benign prostate hyperplasia （BPH） and abnormal lipid metabolism and efficacy of atorvastatin calcium for BPH in the elderly patients. Methods From January 2010 to January 2011, 104 patients with abnormal lipid metabolism were studied for correlation of lipid status and prostate disease. 110 pa- tients with normal lipid metabolism were studied as the control group. The levels of total cholesterol （TC）, triglycerol （TG）, low-densitylipoprotein （LDL-C）, high-densitylipoprotein （HDL-C） and prostatevolume （PV） were measured. To the patients with abnormal lipid metabolism, 20 mg/d atorvastain calcium was administrated and above-mentioned indexes were observed. Results Mean PV in patients with abnormal lipid metabolism was significantly larger than that in the control group （ 54.23 ± 27.33 mm^3 versus 41.87 ± 23.64 mm^3, P〈 0.05 ）. The incidence of BPH in the former was higher than in the latter （88.5% versus 71.8%, P 〈 0.05 ）. No significant PV change was observed after they were treated with 20 mg/d atorvastatin calcium for 6 months. In contrast to mild PV changes were atorvastatin calcium treatment for 6 months, PV significantly decreased with one-year maintenance treatment （51.87 ± 15.23 mm^3 versus 47.34 ± 11.66 mm^3, P〈 0.05）. Conclusions BPH in the elderly patients correlates with abnormal lipid metabolism. Long-term use of atorvastatin calcium may be favorable to improve BPH.